Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of “Buy” from Analysts

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $42.75.

KLRA has been the topic of a number of analyst reports. TD Cowen initiated coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $57.00 target price on the stock. Leerink Partners initiated coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating and a $36.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 target price on the stock. Jefferies Financial Group initiated coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $48.00 target price on the stock. Finally, Wall Street Zen cut Kailera Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Kailera Therapeutics Stock Performance

NASDAQ:KLRA opened at $22.03 on Wednesday. Kailera Therapeutics has a 52 week low of $18.50 and a 52 week high of $28.23. The company’s 50-day simple moving average is $21.72.

Insider Activity

In related news, Director Andrew T. Kaplan purchased 8,398,438 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the purchase, the director owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This represents a 47.03% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Rtw Investments, Lp purchased 500,000 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $8,000,000.00. Following the completion of the purchase, the insider directly owned 10,776,820 shares in the company, valued at $172,429,120. This represents a 4.87% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 10,460,938 shares of company stock worth $167,375,008 in the last ninety days.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.